Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.78 |
| ▸ | HPGDS | O60760 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284142 | 0.88 | PARP1 (1.00) | PARP1HPGDSCES2CES1 | |
| SCHEMBL30151881 | 0.88 | PARP1 (1.00) | PARP1HPGDSCES2CES1 | |
| SCHEMBL18867942 | 0.88 | PARP1 (1.00) | PARP1HPGDSCES2CES1 | |
| SCHEMBL31422694 | 0.88 | PARP1 (0.64) | PARP1ERN1CCNT1CCND1CCNC | |
| SCHEMBL2431097 | 0.88 | PARP1 (0.64) | PARP1ERN1CCNT1CCND1CCNC | |
| SCHEMBL15547657 | 0.87 | CHEK2 (0.67) | PARP1HPGDSCHEK2DPP4DHODH | |
| SCHEMBL1926791 | 0.87 | PARP1 (0.63) | PARP1HPGDSCHEK2ERN1DPP4 | |
| SCHEMBL30958375 | 0.87 | CHEK2 (0.67) | PARP1HPGDSCHEK2DPP4DHODH | |
| Hydrochloric Acid SCHEMBL30460793 | 0.86 | PARP1 (0.96) | PARP1HPGDSCES2CES1 | |
| Hydrochloric Acid SCHEMBL28788495 | 0.86 | PARP1 (0.96) | PARP1HPGDSCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453828-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF FIBROMYALGIA SYNDROME | AstraZeneca AB (SE) | 2004-09-08 | — | — | EP | claimed |
| WO-2003032897-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF FIBROMYALGIA SYNDROME | ASTRAZENECA AB (SE) | 2003-04-24 | — | — | WO | claimed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | claimed |
| CN-103930396-A | Aniline derivatives,their preparation and their therapeutic application | FOVEA PHARMACEUTICALS | 2014-07-16 | — | — | CN | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| CN-100345847-C | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | PARP1 992/4885HPGDS 753/4885CHEK2 4101/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | PARP1 3078/4885HPGDS 3865/4885CHEK2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.